Description

GLP-1/SEMA 10MG

We provide GLP-SEM as a 10MG research presentation containing semaglutide, a 31-amino-acid GLP-1 receptor agonist. Furthermore, semaglutide incorporates structural modifications that improve resistance to DPP-4 degradation and promote albumin binding through a fatty-acid side chain. Consequently, researchers have investigated the compound across incretin signaling, glucose regulation, appetite-related pathways, and metabolic physiology. PubChem identifies semaglutide as a 31-amino-acid polypeptide and GLP-1 receptor agonist, while FDA documentation reports a molecular weight of approximately 4,113.58 g/mol.

Key Attributes — GLP-1/SEMA

• Brand: AvigenLab
• Product Name: GLP-1/SEMA
• Active Compound: Semaglutide
• Quantity: 10MG
• Stated Purity: 99.1%
• Molecular Type: GLP-1 Receptor Agonist Peptide
• Sequence Length: 31 Amino Acids
• Molecular Formula: C₁₈₇H₂₉₁N₄₅O₅₉
• Molecular Weight: 4,113.58 g/mol
• CAS Number: 910463-68-2
• Product Format: Vial
• Classification: Research Use Only
• Human Use: Not For Human Use

The molecular identity, formula, molecular weight, and 31-amino-acid structure correspond with semaglutide records from PubChem and FDA documentation.

GLP-1/SEMA Product Overview

We provide GLP-SEM for research involving GLP-1 receptor signaling, incretin biology, glucose homeostasis, insulin-related pathways, appetite regulation, and metabolic research. Moreover, semaglutide selectively activates the GLP-1 receptor, which serves as the target for native GLP-1.

Additionally, semaglutide contains several structural modifications that distinguish it from native GLP-1. In particular, modification at position 8 increases resistance to DPP-4 degradation, while modification at position 26 enables attachment of a hydrophilic spacer and C18 fatty di-acid that supports albumin binding. Therefore, researchers can investigate both receptor activity and the molecular features responsible for its extended pharmacological profile.

Researchers can explore additional materials through our Online Store.

GLP-1/SEMA Product Identification

We identify GLP-1/SEMA through its 10MG quantity, semaglutide composition, stated 99.1% purity, and vial presentation. Furthermore, semaglutide carries the CAS number 910463-68-2 and the molecular formula C₁₈₇H₂₉₁N₄₅O₅₉.

Accordingly, the molecular identity, peptide length, quantity, purity designation, and physical format provide clear reference points for laboratory inventory and product documentation.

Product Category

We classify GLP-SEM within our research peptide collection for metabolic, endocrine, incretin, receptor-signaling, and glucose-regulation investigations.

Moreover, GLP-1 receptor signaling plays an important role in glucose-dependent insulin secretion and broader metabolic regulation. Likewise, semaglutide research has examined GLP-1 receptor activation alongside effects involving glucose metabolism and appetite-related signaling.

Consequently, the compound provides researchers with a defined molecular subject for studying GLP-1-mediated biological pathways under controlled experimental conditions.

Scientific Characteristics

Semaglutide contains a 31-amino-acid peptide backbone derived from the GLP-1 framework. Furthermore, its molecular design includes substitutions that enhance enzymatic stability and a lipid-containing side chain that facilitates albumin binding.

The resulting molecular formula is C₁₈₇H₂₉₁N₄₅O₅₉, while the molecular weight is approximately 4,113.58 g/mol. Additionally, PubChem describes semaglutide as a polypeptide and lipopeptide with GLP-1 receptor agonist activity.

Therefore, researchers can examine both receptor-mediated signaling and the structural characteristics that influence peptide stability and systemic exposure.

Research Applications

We position GLP-SEM for research involving GLP-1 receptor activity, incretin signaling, glucose homeostasis, insulin-related pathways, appetite regulation, metabolic physiology, and receptor-ligand interactions.

Additionally, semaglutide research provides a well-characterized framework for studying selective GLP-1 receptor activation. Meanwhile, its structural modifications allow researchers to examine how peptide stabilization and albumin association influence biological exposure.

Furthermore, GLP-1 receptor research extends across metabolic regulation, pancreatic signaling, gastrointestinal biology, and central appetite-related pathways. Consequently, the compound remains relevant across several interconnected areas of laboratory investigation.

Product Configuration

We provide GLP-SEM in a 10MG vial carrying a stated 99.1% purity designation. Accordingly, the defined quantity, molecular identity, purity specification, and vial presentation establish straightforward reference points for laboratory inventory.

Additionally, the individual-peptide configuration distinguishes this presentation from combination products containing multiple active compounds. Therefore, researchers can organize the material according to its specific molecular identity, quantity, and physical format.

Product Features

The primary features include a 10MG quantity, 99.1% stated purity, 31-amino-acid semaglutide structure, and clearly defined research-use presentation. Moreover, our product label communicates Not For Human Use | Research Use Only.

Furthermore, the compound’s established GLP-1 receptor activity provides a strong scientific foundation for research involving incretin signaling and metabolic pathways. Consequently, researchers can investigate receptor activation, downstream signaling, and related metabolic mechanisms using a defined molecular subject.

Product Specifications

The molecular specifications correspond with the semaglutide identity recorded by PubChem and FDA documentation.

Intended Research Context

We identify the material as Research Use Only and Not For Human Use. Accordingly, our documentation focuses on laboratory investigation rather than consumer or therapeutic applications.

In particular, researchers can investigate GLP-1 receptor activation, incretin signaling, glucose regulation, insulin-related responses, appetite-associated pathways, and metabolic physiology. Furthermore, the established molecular characterization of semaglutide provides a substantial scientific foundation for examining these pathways.

Nevertheless, researchers should interpret experimental findings according to the specific biological model, formulation, exposure conditions, and measured endpoint.

Packaging Information

We present the product in a clearly labeled 10MG vial featuring our AvigenLab product presentation. The packaging displays the 10MG quantity, communicates the stated 99.1% Purity, and identifies the material as Not For Human Use | Research Use Only.

Additionally, the vial format provides straightforward identification within our research catalog. Researchers can also explore related materials through our Catalog.

Regulatory Information

We classify the product as Research Use Only and maintain the Not For Human Use designation throughout our product documentation. Accordingly, regulatory information concerning approved semaglutide medicines does not constitute regulatory approval for this specific AvigenLab research presentation.

Moreover, semaglutide itself has an established pharmaceutical history and appears in FDA-approved products. However, those approvals apply to specific pharmaceutical formulations, indications, strengths, manufacturing standards, and labeling requirements rather than this research product.

Consequently, we focus our documentation on molecular identity, research relevance, product specifications, and scientific literature.

Storage and Handling

We recommend following the storage and handling conditions specified in the applicable AvigenLab product documentation. Furthermore, researchers should maintain appropriate laboratory handling practices and follow product-specific documentation.

Because peptide stability can depend on formulation, packaging, environmental exposure, and other product-specific variables, we avoid assigning unsupported storage parameters. Consequently, this approach supports consistent laboratory management without introducing assumptions about conditions that may vary between formulations.

Market Availability

Our 10MG presentation provides a defined research peptide configuration within our collection. The quantity, stated purity, molecular identity, 31-amino-acid classification, vial format, and Research Use Only designation create clear reference points for laboratory inventory.

Moreover, semaglutide has a substantial research history within endocrinology, metabolic science, and incretin biology. Likewise, its GLP-1 receptor activity and distinctive structural modifications make it a useful research subject for investigating receptor signaling and prolonged peptide activity.

Product Reference

Our GLP-SEM 10MG presentation provides a defined semaglutide research peptide carrying a stated 99.1% purity designation. We document the material according to its 31-amino-acid structure, molecular characteristics, GLP-1 receptor research relevance, vial configuration, and Research Use Only classification.

Consequently, the product provides researchers with a clearly identified material for investigating GLP-1 receptor signaling, incretin pathways, glucose homeostasis, appetite-related mechanisms, and metabolic physiology. Furthermore, the established molecular literature surrounding semaglutide provides a strong reference base for continued investigation into GLP-1-mediated biological activity.

For additional product information, researchers can also visit our Shop.